KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Other Operating Expenses (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Other Operating Expenses for 16 consecutive years, with $435.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses rose 628.44% to $435.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $639.0 million, a 177.27% increase, with the full-year FY2025 number at $639.0 million, up 177.27% from a year prior.
  • Other Operating Expenses was $435.7 million for Q4 2025 at Halozyme Therapeutics, up from $73.0 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $435.7 million in Q4 2025 to a low of $15.9 million in Q1 2022.
  • A 5-year average of $70.0 million and a median of $58.6 million in 2024 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: dropped 17.83% in 2021, then soared 628.44% in 2025.
  • Halozyme Therapeutics' Other Operating Expenses stood at $21.6 million in 2021, then soared by 116.2% to $46.7 million in 2022, then skyrocketed by 50.11% to $70.1 million in 2023, then decreased by 14.62% to $59.8 million in 2024, then skyrocketed by 628.44% to $435.7 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's Other Operating Expenses are $435.7 million (Q4 2025), $73.0 million (Q3 2025), and $64.1 million (Q2 2025).